IBRX_OUT_1 [2025-03-27 16:04:50 -0400] 2102 Bytes | 617 tokens | Cum: 617 tkns (7.71% of 8k)
==========================================================================

Listen up, partner—it's 4:04:49 PM on Thu Mar 27, 2025 -0400, and I’m revved up about ImmunityBio (IBRX), climbing from 2.78 to 3.35. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for ImmunityBio:

C1 - Mar-26-25 06:00AM - ImmunityBio to Host Investor Day
C2 - Mar-25-25 05:41PM - Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket?
C3 - Mar-13-25 09:00AM - ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
C4 - Mar-03-25 07:30AM - ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
C5 - Mar-01-25 04:09PM - Why ImmunityBio, Inc. (IBRX) Soared on Friday
C6 - Feb-27-25 07:10PM - ImmunityBio Receives FDA RMAT Designation for ANKTIVA and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
C7 - Feb-20-25 12:00PM - Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz
C8 - Feb-19-25 09:00AM - FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on ImmunityBio (IBRX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

IBRX_OUT_3 [2025-03-27 16:04:55 -0400] 583 Bytes | 176 tokens | Cum: 795 tkns (9.94% of 8k)
==========================================================================

Showing C4 (chunk 1 of 1): C4:
**ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024**
Date: Mar-03-25 07:30AM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20250303380017/en/

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20250303380017/en/

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBRX_OUT_5 [2025-03-27 16:04:57 -0400] 963 Bytes | 293 tokens | Cum: 1202 tkns (15.02% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-27T14:15:51Z - Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness...
A2 - 2025-03-25T21:41:42Z - Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket?...
A3 - 2025-03-24T20:26:45Z - Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Inv...
A4 - 2025-03-18T10:21:07Z - Clearwater Capital Advisors LLC Acquires 363,870 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)...
A5 - 2025-03-16T05:40:43Z - ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IBRX_OUT_7 [2025-03-27 16:05:02 -0400] 1098 Bytes | 301 tokens | Cum: 1505 tkns (18.81% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Avis Budget Gr (NASDAQ:CAR), Concentrix (NASDAQ:CNXC)**Date: 2025-03-27Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/03/44515668/concentrix-posts-better-than-expected-earnings-joins-soleno-therapeutics-petco-health-and-wellness-millerknoll-and-other-big-stocks-moving-higher-on-thursdayU.S. stocks were lower, with the Dow Jones index falling around 0.2% on Thursday.

Shares of Concentrix Corporation CNXC rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.

Concentrix reported quarterly earnings of $2.79 per share, which beat the analyst con

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBRX_OUT_9 [2025-03-27 16:05:04 -0400] 1036 Bytes | 316 tokens | Cum: 1885 tkns (23.56% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-08-23T20:30:00Z - HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
B2 - 2024-06-26T13:41:00Z - ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
B3 - 2024-03-20T15:41:03Z - Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
B4 - 2024-02-26T18:57:55Z - Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
B5 - 2024-02-26T13:18:20Z - Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
B6 - 2024-02-26T12:03:47Z - Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBRX_OUT_11 [2025-03-27 16:05:10 -0400] 1102 Bytes | 290 tokens | Cum: 2177 tkns (27.21% of 8k)
==========================================================================

Showing B3 (chunk 1 of 2): B3:
**Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/03/37851198/sportradar-group-posts-upbeat-earnings-joins-kingsoft-cloud-braskem-and-other-big-stocks-moving-highU.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Wednesday.
Shares of Sportradar Group AG (NASDAQ: SRAD) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter results and authorized a $200 million share repurchase program.
Sportradar posted quarterly earnings of 8 cents per share, beating market estimates of 4 cents per share. The company’s quarterly sales came in at $271.88 million, beating market expectations of $271.46 million, according to data from Benzinga Pro.
Sportradar Group shares jumped 10.7% to

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBRX_OUT_13 [2025-03-27 16:05:12 -0400] 794 Bytes | 204 tokens | Cum: 2476 tkns (30.95% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-03 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

The following discussion and analysis of our financial condition and results of operations should be read together with the description of our business that appears in Part I, Item 1....

S2 - 2025-03-03 8-K Item 2.02 Results of Oper and Fin Cond.

On March 3, 2025, ImmunityBio, Inc. (the Company) issued a press release providing a business update and announcing its financial results for the fourth quarter and year ended December 31, 2024, and its financial position...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBRX_OUT_15 [2025-03-27 16:05:13 -0400] 1098 Bytes | 243 tokens | Cum: 2721 tkns (34.01% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial condition and results of operations should be read together with the description of our business that appears in Part I, Item 1. Business and the consolidated financial statements and related notes thereto in Part II, Item 8. Financial Statements and Supplementary Data of this Annual Report. This discussion contains forward-looking statements as a result of many factors, including those set forth under Part I, Item 1. Business Forward-Looking Statements and Item 1A. Risk Factors and elsewhere in this Annual Report. These statements are based on our managements beliefs and assumptions and on information currently available to our management. Actual results could differ materially from those discussed in or implied by such forward-lookin

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBRX_OUT_17 [2025-03-27 16:05:19 -0400] 1098 Bytes | 230 tokens | Cum: 2953 tkns (36.91% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): g statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in Part I, Item 1A. Risk Factors . Except as required by law, we do not undertake any responsibility to update any of these factors or to announce publicly any revisions to any of the forward-looking statements contained in this or any document, whether as a result of new information, future events, or otherwise.

ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The companys range of immunotherapy platforms, alone and together, act to drive an immune response with the goal of creating durable immune memory generating safe protection against disease. We are applying our science and platforms

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBRX_OUT_19 [2025-03-27 16:05:21 -0400] 1098 Bytes | 253 tokens | Cum: 3328 tkns (41.60% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.

Our Approved Product ANKTIVA

Our lead biologic product ANKTIVA is a novel first-in-class IL-15 receptor superagonist antibody-cytokine fusion protein. On April 22, 2024, the FDA approved our product, ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors (the approved product). ANKTIVA was approved with a label indicating an immunological mechanism of action which proliferates and activates NK, CD8+ and m

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBRX_OUT_21 [2025-03-27 16:05:28 -0400] 1098 Bytes | 263 tokens | Cum: 3593 tkns (44.91% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): emory T cells without the proliferation of immunosuppressive T-reg cells leading to the establishment of memory T cells. We began commercial distribution of our approved product in May 2024.

We believe there is potential for ANKTIVA to become a therapeutic foundation across all phases of treatment, including in adjunctive therapy, to amplify, reactivate or extend the efficacy of standard of care. ANKTIVA is being clinically evaluated in multiple oncology indications. We believe that other oncology indications with registration potential for ANKTIVA include other types of NMIBC ( BCG-unresponsive papillary, BCG-nave CIS and BCG-nave papillary), lung, colorectal, prostate and ovarian cancers, and GBM and NHL.

Data from multiple clinical trials suggest ANKTIVA has potential to enhance the activity of therapeutic mAbs, including CPIs (e.g., pembrolizumab/Keytruda), across a wide range of

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBRX_OUT_23 [2025-03-27 16:05:30 -0400] 1098 Bytes | 270 tokens | Cum: 4008 tkns (50.10% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): tumor types, including lung cancer. Further, ANKTIVA has been observed to increase lymphocyte count in healthy adults, making it a potential therapy to rescue lymphopenia. We are also exploring or pursuing several other studies of ANKTIVA in combination with our other product candidates, including in prostate cancer (ANKTIVA in combination with hAd5 PSA), colon cancer (ANKTIVA in combination with hAd5 TriAd), and NHL (ANKTIVA in combination with rituximab). We are also exploring ANKTIVA in infectious diseases, including HIV and long COVID.

Table of Conten t s

Significant Developments

The following is a summary of selected significant developments affecting our business that occurred since the filing of our Quarterly Report dated September 30, 2024 with the SEC on November 12, 2024:

ANKTIVA received a J-code assigned by the CMS in the U.S. for ANKTIVA, which became effective Jan

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBRX_OUT_25 [2025-03-27 16:05:43 -0400] 5983 Bytes | 1806 tokens | Cum: 5816 tkns (72.70% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-------------------------+
| Volume: 14,674,792 | Perf Month: 10.18% | Option/Short: Yes / Yes | Sales Y/Y TTM: 2270.58% |
+--------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 5.98M | Perf Quarter: 23.80% | Short Float: 67.07% | ROE: - |
+--------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 2.52 | Index: RUT | Short Ratio: 9.96 | ROI: -141.63% |
+--------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 59.58 | Market Cap: 2.82B | Short Interest: 59.54M | Sales Surprise: -21.54% |
+--------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.25 | Shs Outstand: 852.74M | Beta: 0.43 | EPS Surprise: 55.00% |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 13.60% | Shs Float: 88.78M | Sales Q/Q: 5333.09% | P/E: - |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA50: 6.63% | Inst Own: 9.90% | Sales past 5Y: 651.00% | Earnings: Mar 03 BMO |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -20.17% | Insider Own: 89.60% | Employees: 680 | |
+--------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 20.20% | Insider Trans: 0.00% | Debt/Eq: - | |
+--------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: ImmunityBio, Inc. (IBRX) by Simon Barry J. (Unknown Title) on 2025-02-22
- Common Stock: 15243 shares at $0 (D)
- Common Stock: 5453 shares at $3.42 (D)
- Restricted Stock Units: 15243 shares at $0 (D)

Inside Trans: ImmunityBio, Inc. (IBRX) by Adcock Richard (CEO & President) on 2025-02-22
- Common Stock: 152439 shares at $0 (D)
- Common Stock: 78167 shares at $3.42 (D)
- Restricted Stock Units: 152439 shares at $0 (D)

Inside Trans: ImmunityBio, Inc. (IBRX) by Sachs David C. (Chief Financial Officer) on 2025-02-22
- Common Stock: 40650 shares at $0 (D)
- Common Stock: 15860 shares at $3.42 (D)
- Restricted Stock Units: 40650 shares at $0 (D)

Inside Trans: ImmunityBio, Inc. (IBRX) by SOON-SHIONG PATRICK (See remarks) on 2025-02-22
- Common Stock: 114329 shares at $0 (D)
- Common Stock: 42071 shares at $3.42 (D)
- Restricted Stock Units: 114329 shares at $0 (D)

Inside Trans: ImmunityBio, Inc. (IBRX) by LAUER REGAN J (Chief Accounting Officer) on 2025-02-22
- Common Stock: 4065 shares at $0 (D)
- Common Stock: 1669 shares at $3.42 (D)
- Restricted Stock Units: 4065 shares at $0 (D)

Inside Trans: ImmunityBio, Inc. (IBRX) by Adcock Richard (CEO & President) on 2025-02-10
- Restricted Stock Units: 822368 shares at $0 (D)
- Stock Option (right to buy): 2812500 shares at $0 (D)

Inside Trans: ImmunityBio, Inc. (IBRX) by Sachs David C. (Chief Financial Officer) on 2025-02-10
- Restricted Stock Units: 246710 shares at $0 (D)
- Stock Option (right to buy): 843750 shares at $0 (D)

Inside Trans: ImmunityBio, Inc. (IBRX) by LAUER REGAN J (Chief Accounting Officer) on 2025-02-10
- Restricted Stock Units: 16447 shares at $0 (D)
- Stock Option (right to buy): 56250 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 7332000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -587880000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.36
Average Volume: 5869012.43
30-Day High: 3.36
30-Day Low: 2.71

[Detailed Financials: Q3 2024]
- Total Assets: $364,570,000.0
- Total Liabilities: $1,108,732,000.0
- Total Equity: $-744,162,000.0
- Current Assets: $163,150,000.0
- Current Liabilities: $60,960,000.0

[Income Statement: Q3 2024]
- Revenue: $6,106,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.12

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-18,149,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $444,325,000.0
- Total Liabilities: $1,141,703,000.0
- Total Equity: $-697,378,000.0
- Current Assets: $242,830,000.0
- Current Liabilities: $62,110,000.0

[Income Statement: Q2 2024]
- Revenue: $1,047,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.2

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-2,943,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

IBRX_OUT_27 [2025-03-27 16:05:48 -0400] 676 Bytes | 167 tokens | Cum: 6232 tkns (77.90% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

IBRX_IN_29 [2025-03-27 16:05:49 -0400] 126 Bytes | 29 tokens | Cum: 6334 tkns (79.17% of 8k)
==========================================================================

====================================
[2025-03-27 13:05:49] # Analysis Completed
Elapsed Time: 60.41 seconds